Lu solution is widely used in nuclear medicine, particularly in targeted radionuclide therapy. It serves as a key agent in the treatment of neuroendocrine tumors and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. The radioactive properties allow for precise delivery of radiation to cancer cells, minimizing damage to surrounding healthy tissue. Its ability to bind with specific peptides enables highly selective targeting, improving therapeutic outcomes. Additionally, Lu solution is used in palliative care for bone metastases due to its affinity for bone tissue, helping reduce pain and improve quality of life. Ongoing research explores its potential in treating other types of cancers using tailored radiopharmaceuticals.